 Blood samples: 50 ml of blood in heparin will be collected from each patient no more than 2 months before the beginning of treatment with Adalimumab and 3 and six months after the first administration of the drug 2 weeks. DAS-28, HAQ scores, comorbidities and concomitant medication will be determined and recorded at the same times and the coded data stored in a secure database. 